Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 263

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

Open access
Weigelt, Britta, Comino-Méndez, Iñaki, de Bruijn, Ino, Tian, Lei, Meisel, Jane L., García-Murillas, Isaac, Fribbens, Charlotte, Cutts, Ros, Martelotto, Luciano G., Ng, Charlotte K.Y., Lim, Raymond S., Selenica, Pier, Piscuoglio, Salvatore, Aghajanian, Carol, Norton, Larry, Murali, Rajmohan, Hyman, David M., Borsu, Laetitia, Arcila, Maria E., Konner, Jason, Reis-Filho, Jorge S., Greenberg, Roger A., Robson, Mark E., Turner, Nicholas C.·2017·Clinical Cancer Research

Abstract

Purpose: Resistance to platinum-based chemotherapy or PARP inhibition in germline BRCA1 or BRCA2 mutation carriers may occur through somatic reversion mutations or intragenic deletions that restore BRCA1 or BRCA2 function. We assessed whether BRCA1/2 reversion mutations could be identified in circulating cell-free DNA (cfDNA) of patients with ovarian or breast cancer previously treated with platinum and/or PARP inhibitors. Experimental Design: cfDNA from 24 prospectively accrued patients with germline BRCA1 or BRCA2 mutations, including 19 patients with platinum-resistant/refractory ovarian cancer and five patients with platinum and/or PARP inhibitor pretreated metastatic breast cancer, was subjected to massively parallel sequencing targeting all exons of 141 genes and all exons and introns of BRCA1 and BRCA2. Functional studies were performed to assess the impact of the putative BRCA1/2 reversion mutations on BRCA1/2 function. Results: Diverse and often polyclonal putative BRCA1 or BRCA2 reversion mutations were identified in cfDNA from four patients with ovarian cancer (21%) and from two patients with breast cancer (40%). BRCA2 reversion mutations were detected in cfDNA prior to PARP inhibitor treatment in a patient with breast cancer who did not respond to treatment and were enriched in plasma samples after PARP inhibitor therapy. Foci formation and immunoprecipitation assays suggest that a subset of the putative reversion mutations restored BRCA1/2 function. Conclusions: Putative BRCA1/2 reversion mutations can be detected by cfDNA sequencing analysis in patients with ovarian and breast cancer. Our findings warrant further investigation of cfDNA sequencing to identify putative BRCA1/2 reversion mutations and to aid the selection of patients for PARP inhibition therapy. Clin Cancer Res; 23(21); 6708–20. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0544

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 263

Metadata

Authors
Weigelt, B., Comino-Méndez, I., de Bruijn, I., Tian, L., Meisel, J. L., García-Murillas, I., Fribbens, C., Cutts, R., Martelotto, L. G., Ng, C. K. Y., Lim, R. S., Selenica, P., Piscuoglio, S., Aghajanian, C., Norton, L., Murali, R., Hyman, D. M., Borsu, L., Arcila, M. E., Konner, J., Reis-Filho, J. S., Greenberg, R. A., Robson, M. E., & Turner, N. C.
Venue
Clinical Cancer Research
Published
2017-10-31
Volume
23
Issue
21
Pages
6708-6720
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2741214285
Cited by
263
References
48
FWCI
14.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0544
The paper
Weigelt, B., Comino-Méndez, I., de Bruijn, I., Tian, L., Meisel, J. L., García-Murillas, I., Fribbens, C., Cutts, R., Martelotto, L. G., Ng, C. K. Y., Lim, R. S., Selenica, P., Piscuoglio, S., Aghajanian, C., Norton, L., Murali, R., Hyman, D. M., Borsu, L., Arcila, M. E., . . . Turner, N. C. (2017). Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0544

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.